Ipca’s profit surged on a low base, but quarterly margin fell 2.03 points
Year-on-year profit benefited from other-income and tax effects, while sequentially higher costs and interest weakened operating performance.
Filed 29 May 2026, 13:51 IST · Ipca Laboratories Ltd (IPCALAB)
Key takeaways
- Consolidated net profit rose 379.28% year on year, but the increase was amplified by the swing in other income and a 25.64 percentage-point fall in the tax rate.
- Operating margin fell 2.03 percentage points sequentially to 20.26% as expenses grew 2.45% while revenue declined 0.17%.
- The stock fell 3.05% on the result day, close to its 3.07% median absolute post-results move, with six of its last eight reactions negative.
Price around the results
Sequential margin reversal follows two stronger quarters
Consolidated revenue was broadly flat sequentially, but expenses rose 2.45%, causing operating profit to fall 9.28% and operating margin to contract 2.03 percentage points. Interest expense also increased 14.64%, adding to the pressure below operating profit. The margin had improved from 18.04% in Q1FY26 to 21.32% in Q2FY26 and 22.29% in Q3FY26, so Q4FY26 reversed that recent recovery rather than extending a multi-quarter decline.
Year-on-year profit growth carries clear quality caveats
Revenue grew 6.31% year on year while expenses grew 4.77%, lifting operating margin by 1.17 percentage points and operating profit by 12.83%. Net profit growth of 379.28% was much larger because other income moved from negative Rs 181.02 cr to Rs 45.21 cr, while the tax rate fell 25.64 percentage points to 23.66%. Other income accounted for 11.25% of pre-tax profit, so the reported profit increase does not represent operating performance alone.
Operating margin trails the reported healthcare peer median
Ipca’s 20.26% operating margin was 3.12 percentage points below the 23.38% median for 48 healthcare peers that had reported the same quarter. The company ranked 17th from the bottom on this measure, placing its margin below the sector comparison despite the year-on-year improvement.
Initial market fall was typical for Ipca, not unusually large
The stock fell 3.05% on the result day and was down 5.21% on the next trading day, before gaining 4.42% over five trading days. The initial move was close to the 3.07% median absolute reaction across the last eight results, during which the stock fell after six announcements and rose after two.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹2,388 cr | ₹2,393 cr | -0.17% | +6.31% |
| Other income | ₹45 cr | ₹37 cr | +20.69% | — |
| Expenses | ₹1,905 cr | ₹1,859 cr | +2.45% | +4.77% |
| Operating profit | ₹484 cr | ₹533 cr | -9.28% | +12.83% |
| Operating margin (%) | 20.26% | 22.29% | — | — |
| Interest | ₹20 cr | ₹18 cr | +14.64% | -6.09% |
| Depreciation | ₹107 cr | ₹108 cr | -0.42% | +7.01% |
| Profit before tax | ₹402 cr | ₹446 cr | -9.84% | +218.31% |
| Tax | ₹95 cr | ₹82 cr | +16.01% | +52.76% |
| Net profit | ₹307 cr | ₹364 cr | -15.67% | +379.28% |
| EPS (₹) | ₹11.79 | ₹12.86 | -8.32% | +341.57% |
Operating margin of 20.26% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -3.05% | -1.55% |
| Next session | -5.21% | — |
| 5 sessions | +4.42% | +6.68% |
| 15 sessions | +0.85% | — |
| 30 sessions | +15.96% | — |
Volume on the results session was 3.19× its 20-day average.
What to watch
- Whether operating margin recovers from 20.26% after the 2.03 percentage-point sequential decline.
- Whether revenue returns to growth after the 0.17% sequential decline while expenses remain below the 2.45% sequential increase seen in Q4FY26.
- Whether other income remains a material contributor after accounting for 11.25% of pre-tax profit.